By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ligand Pharmaceuticals Inc. 

3911 Sorrento Valley Boulevard
Suite 110
San Diego  California  92121  U.S.A.
Phone: 858-550-7500 Fax: n/a


SEARCH JOBS




Collaborations

GlaxoSmithKline  - In 1995, we entered into a research and development collaboration with SmithKline Beecham (now GlaxoSmithKline) to use our proprietary expertise to discover and characterize small-molecule, orally bioavailable drugs to control hematopoiesis (the formation and development of blood cells) for the treatment of a variety of blood cell deficiencies. Eltrombopag and a back up compound, SB-559448, resulted from this collaboration. These compounds are orally active, non-peptide, small molecule thrombopoietin (TPO) mimetics for the treatment of thrombocytopenia (low platelet counts). Eltrombopag is in Phase III clinical trials for immune thrombocytopenic purpura (ITP). GlaxoSmithKline plans to file an NDA for the ITP indication in late 2007/early 2008. A Phase III clinical trial in patients with hepatitis C is planned in 2H07. In addition, Phase I/II studies are ongoing in patients with chemotherapy-induced thrombocytopenia. The backup compound, SB-559448, is in Phase I clinical trials.

Pfizer  - We collaborated with Pfizer to develop therapies for osteoporosis. The collaboration produced lasofoxifene (Oporia™), that Pfizer has advanced through late-stage clinical development. Lasofoxifene (Oporia) is a SERM that is being developed for the treatment and prevention of post-menopausal osteoporosis and vaginal atrophy. Pfizer plans to re-file the lasofoxifene NDA for the prevention of osteoporosis in late 2007.

TAP Pharmaceutical Products Inc.  - In June 2001, we entered into a joint research and development alliance with TAP Pharmaceutical Products discovery and develop selective androgen receptor modulators (SARMs) for the treatment of osteoporosis, frailty, wasting disorders (such as cancer cachexia), and male hypogonadism. LGD-2941 is a product of that collaboration. LGD-2941 is in Phase I clinical trials.

Wyeth  - In 1994, we entered into a research and development collaboration with Wyeth-Ayerst Laboratories (now Wyeth) to discover and develop drugs that interact with estrogen and progesterone receptors for use in hormone therapy, anti-cancer therapy, gynecological diseases and central nervous system disorders associated with menopause and fertility control. Bazedoxifene, a selective estrogen receptor modulator (SERM), is the product of this collaboration.

Bazedoxifene (Viviant) is a synthetic drug that was designed to increase bone density while protecting breast and uterine tissue. Wyeth is developing bazedoxifene (Viviant) for the treatment and prevention of post-menopausal osteoporosis. FDA action on the Viviant NDA for the prevention of osteoporosis is expected in late 2007. Wyeth plans to submitted a second NDA for Viviant for the treatment of osteoporosis in 3Q07.

Wyeth is developing bazedoxifene in combination with Premarin® (Aprela) as a progesterone-free treatment for menopausal symptoms including osteoporosis and hot flush. Wyeth plans to file an NDA for Aprela in late 2007.





Company News
Dr. Christel Iffland Joins Ligand (LGND) As Vice President, Antibody Technologies, Expands Team Focused On Omniab Drug Discovery Platform 2/15/2017 8:58:38 AM
Reminder: Ligand (LGND) To Host Analyst Day On February 28th In New York City 2/14/2017 8:27:47 AM
Ligand (LGND) Release: Pharma To Host Analyst Day On February 28th In New York City 1/25/2017 8:02:04 AM
Ligand (LGND) Release: Pharma To Report Fourth Quarter And Full Year 2016 Results On February 23rd 1/24/2017 8:35:54 AM
Ligand (LGND) Enters Into Worldwide OmniAb Platform License Agreement With Ono Pharma (OPHLY) 12/22/2016 11:03:26 AM
Ligand (LGND) Enters Commercial License And Supply Agreements For Captisol-Enabled Trametinib 12/22/2016 10:31:51 AM
Ligand (LGND) Partner Retrophin (RTRX) Reports Additional Positive Data From Phase 2 DUET Study Of Sparsentan In Focal Segmental Glomerulosclerosis At American Society of Nephrology Kidney Week 2016 11/21/2016 12:13:53 PM
Ligand (LGND) Reports Third Quarter 2016 Financial Results 11/4/2016 10:54:02 AM
Ligand (LGND) Partner Melinta Submits Baxdela New Drug Application For Hospital-Treated Skin Infections 10/24/2016 8:43:25 AM
Ligand (LGND) Announces Third Quarter 2016 Earnings Release Date And Participation In The Stephens Fall Investment Conference 10/13/2016 12:05:14 PM
12345678910...
//-->